Charles Knupp, MD
Hematology & Oncology · Greenville, NCNPI 1154313575
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $261 of the $360 with a category attached, or 72.5%. 11 manufacturers reported payments, led by Incyte Corporation at 27.5% of the total. Reporting peaked in 2019 at $247 and has fallen 94.2% since, to $14 in 2024. That places this record below the midpoint for hematology & oncology clinicians in NC, where the typical reported total is $1,703.
Across 18 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$99
- Johnson & Johnson$78
- Tesaro, Inc.$42
- Lilly USA, LLC$24
- EMD Serono, Inc.$23
- Novartis$19
- plus $75 from 5 others
Across 30 payments — averaging $4614.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Agios Pharmaceuticals, Inc.$138K
What the payments were for
- Food & beverage$26173%
- Education$9927%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 1 | $99 |
| Johnson & Johnson | 5 | $78 |
| Tesaro, Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $24 |
| EMD Serono, Inc. | 2 | $23 |
| Novartis | 1 | $19 |
| Gilead | 1 | $17 |
| Dendreon Pharmaceuticals LLC | 1 | $16 |
| Amgen | 1 | $16 |
| Masimo Corporation | 1 | $14 |
| Merck | 1 | $12 |
How this compares
$360 in reported general payments places this provider in the 25th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 44 | $842,779 |
| ImbruvicaIbrutinib | 27 | $356,335 |
| Xtampza ErOxycodone Myristate | 58 | $64,728 |
| EndariGlutamine | 14 | $46,648 |
| OxycontinOxycodone Hcl | 27 | $37,518 |
| EliquisApixaban | 14 | $7,929 |
| Mycophenolate Mofetil | 11 | $4,090 |
| Oxycodone Hcl | 212 | $3,993 |
| Hydroxyurea | 80 | $2,751 |
| Morphine Sulfate ErMorphine Sulfate | 64 | $2,241 |
| Enoxaparin Sodium | 12 | $2,226 |
| Deferasirox | 14 | $1,091 |
| Lidocaine | 12 | $947 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $370 |
| Gabapentin | 20 | $369 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Greenville
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
- Jared WeissChapel Hill$217K
- Joshua ZeidnerChapel Hill$208K
- Taewoong ChoiDurham$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.